<DOC>
	<DOCNO>NCT00004808</DOCNO>
	<brief_summary>OBJECTIVES : I . Identify preferred oral fluconazole dose regimen patient non-acute histoplasmosis blastomycosis , ulcerocutaneous deep sporotrichosis . II . Study safety efficacy fluconazole patient .</brief_summary>
	<brief_title>Phase II Pilot Study Fluconazole Histoplasmosis , Blastomycosis , Sporotrichosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Patients stratify participate institution type infection . Patients blastomycosis randomly assign moderate- versus high-dose oral fluconazole . Based clinical response , dose increase 1 2 month patient moderate-dose group . Patients high-dose group receive fix dose fluconazole . Patients histoplasmosis sporotrichosis nonrandomly treat moderate-dose fluconazole . Therapy administer daily 3 month beyond stabilization infection ( maximum 24 month ) , total 6 month infection stabilize within 3 month . Fluconazole may administer intravenously ( maximum 7 day ) oral dose tolerate . Concurrent systemic intrathecal antifungal , immunostimulants , lymphocyte replacement prohibit . Investigational agent approve agent give investigational indication also permit study . Patients follow 3 , 6 , 12 month .</detailed_description>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Blastomycosis</mesh_term>
	<mesh_term>Sporotrichosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Clinical , radiographic , nuclear medicine , similar study finding compatible active infection following : Histoplasma capsulatum Blastomyces dermatiditis Sporothrix schenckii At least 1 positive culture within 8 week prior entry Diagnostic histopathology fulfills requirement confirm second independent reviewer Sporotrichosis , i.e . : Ulcerocutaneous disease limit local regional skin lymphatics OR Deep infection tissue sit locoregional skin/lymphatics Histoplasmosis blastomycosis acute pulmonary infection sole site disease eligible progressive , i.e . : Clinically radiographically apparent new lesion continue increase old lesion 20 day acute illness onset Positive culture histopathology least 20 day illness onset Relapsed disease eligible , follow : Clinical evidence active disease Positive culture within 8 week prior entry Histopathologic evidence alone acceptable entry No 3 day systemic amphotericin B ketoconazole since positive culture Infection site present study entry , i.e. , prior surgical removal No active meningeal central nervous system infection Diagnostic test require symptomatic No immediately lifethreatening infection Patient Characteristics Life expectancy : At least 1 week Hepatic : AST ALT great 5 time normal Alkaline phosphatase great 5 time normal Bilirubin great 5 time normal PT great 5 second normal control correct vitamin K Other : No HIV infection No AIDS ( Centers Disease Control Prevention criterion ) No requirement follow : Barbiturates Phenytoin Oral hypoglycemics Coumarintype anticoagulants No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>blastomycosis</keyword>
	<keyword>fungal infection</keyword>
	<keyword>histoplasmosis</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>sporotrichosis</keyword>
</DOC>